← Leaderboards
Karen E Friday
Tulane University Of Louisiana
$74,356
Attributed
$74,356
Total exposure
8
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$74,356 · 8
By mechanism
M01$74,356 · 8
Top collaborators
No co-investigators on record.
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Ivona Pandrea$33,088,190
- Lu Qi$19,868,722
- Vivian A Fonseca$5,822,487
- Marc A Czapla$42,344
- Juan J. L. Lertora$4,837,795
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchLow Density LipoproteinHuman Therapy EvaluationChemopreventionCardiovascular Disorder PreventionTriglyceridesNoninsulin Dependent Diabetes MellitusDiabetes Mellitus TherapyAntihypercholesterolemic AgentClinical TrialsEnzyme ActivityDrug Screening /EvaluationCoronary DisorderBlood Lipoprotein MetabolismClinical Trial Phase IExerciseLipoprotein LipaseRacial /Ethnic DifferenceApolipoproteinsEatingCardiovascular DisorderApolipoprotein BDisease /Disorder Proneness /Risk
Grant awards (14)
BYPASS ANGIOPLASTY REVASCULARIZATION INVESTIGATION 2 DIABETES (BARI 2D)$4,141
M01 · FY2005 · RR
Bypass Angioplasty Revascularization Investigation NIDDM$14,315
M01 · FY2004 · RR
ESTROGEN REPLACEMENT IN LIPOPROTEIN OXIDATION &POSTPRANDIAL TRIGLYCERIDE$0
M01 · FY2001 · RR
EFFECTS OF RACE &APOLIPOPROTEIN &GENOTYPE ON LIPOPROTEIN LIPASE ACT$0
M01 · FY2001 · RR
ATORVASTATIN AS COMPARED TO SIMVASTATIN WHEN USED TO CONTROL MIXED DY$0
M01 · FY2001 · RR
LDL-C LOWERING IN CORONARY HEART DISEASE$0
M01 · FY2001 · RR
FLUVASTATIN COMPARED TO ATORVASTATIN AND SIMVASTATIN$0
M01 · FY2001 · RR
HDL LIPOPROTEIN METABOLISM IN BLACK AND WHITE ADULTS$11,180
M01 · FY2000 · RR
EFFECTS OF RACE &APOLIPOPROTEIN &GENOTYPE ON LIPOPROTEIN LIPASE ACT$11,180
M01 · FY2000 · RR
ESTROGEN REPLACEMENT IN LIPOPROTEIN OXIDATION &POSTPRANDIAL TRIGLYCERIDE$11,180
M01 · FY2000 · RR
ATORVASTATIN AS COMPARED TO SIMVASTATIN WHEN USED TO CONTROL MIXED DY$11,180
M01 · FY2000 · RR
2 DOSES OF BAYCOL &PRAVACHOL IN TREATMENT OF HYPERCHOLESTEROLEMIA$11,180
M01 · FY2000 · RR
LDL-C LOWERING IN CORONARY HEART DISEASE$0
M01 · FY2000 · RR
FLUVASTATIN COMPARED TO ATORVASTATIN AND SIMVASTATIN$0
M01 · FY2000 · RR